(Q48864652)

English

Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety?

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

0 references

Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

pharmacotherapy

0 references

David C. Atkins

3

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Peter Roy-Byrne

6

object named as

Peter Roy-Byrne

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

author name string

Babak Roshanaei-Moghaddam

1

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Michael C Pauly

2

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Scott A Baldwin

4

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Murray B Stein

5

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

publication date

23 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

28

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

7

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

560-567

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

Empirically supported psychological interventions: controversies and evidence

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

The medical management of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

The pharmacologic treatment of anxiety disorders: a review of progress

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive therapy vs medications in the treatment of moderate to severe depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program

2 references

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive-Behavior Therapy (CBT) for Panic Disorder: Relationship of Anxiety and Depression Comorbidity with Treatment Outcome

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Diagnostic comorbidity in adults with generalized anxiety disorder: impact of comorbidity on psychotherapy outcome and impact of psychotherapy on comorbid diagnoses.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Does cognitive-behavioral therapy response among adults with obsessive-compulsive disorder differ as a function of certain comorbidities?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Defining empirically supported therapies

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

A re-evaluation of random-effects meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Combination treatment for acute depression is superior only when psychotherapy is added to medication.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, posttreatment outcomes, and six-month follow-up

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

National Institute of Mental Health Treatment of Depression Collaborative Research Program

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Cognitive Therapy and Pharmacotherapy for Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Treating depression in predominantly low-income young minority women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Should OCD be classified as an anxiety disorder in DSM-V?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Conducting Meta-Analyses in R with the metafor Package

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

24 Hour Urinary Dehydroepiandosterone Sulfate in Unipolar Depression Treated with Cognitive and/or Pharmacotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

21 January 2018

Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine, Clomipramine, and Cognitive Therapy in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of treatments for generalized anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

The behavioural treatment of obsessional-compulsive disorders, with and without clomipramine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between paroxetine and behaviour therapy in patients with posttraumatic stress disorder (PTSD): A pilot study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of alprazolam and behavior therapy in treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical depression: Comparative efficacy of outpatient treatments

1 reference

https://api.crossref.org/works/10.1002%2FDA.20829

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20829

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 February 2018

http://europepmc.org/abstract/MED/21608087

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48864652&oldid=1994303598"